Skyclarys Decision Shocks Families | Cork News

Ireland’s HSE has rejected funding for Skyclarys, a drug that could treat Friedreich’s ataxia — a devastating genetic disorder that killed 13-year-old Rory Coady and affects his brother Paudie. Despite a review group endorsing the drug, the HSE’s decision has sparked outrage, with politicians demanding transparency and families pleading for urgent action. While the HSE insists its process is open, families say communication failed them — especially after meeting the Taoiseach who promised to push for approval. With European nations already funding the drug and pressure mounting, all eyes are on an August 25th leadership meeting that could change lives. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/eeb3e153eb261013